APPLICATION NUMBER:
22-362

APPROVAL LETTER
NDA 22362  
NDA 21176/S-022

DEPARTMENT OF HEALTH & HUMAN SERVICES
Public Health Service
Food and Drug Administration
Rockville, MD  20857

Daiichi Sankyo, Inc.  
Attention: Paulette F. Kosmoski  
Executive Director, US/EU & Regional Regulatory Affairs-CMC  
399 Thornall Street  
Edison, NJ 08837

Dear Ms. Kosmoski:

Please refer to your new drug application (NDA 22362) dated August 15, 2008, received August 15, 2008, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Welchol (colesevelam HCL) for Oral Suspension.

We also refer to your supplemental new drug application (NDA 21176/S-022) dated December 10, 2008, received December 10, 2008, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Welchol (colesevelam HCl) Tablets.

We acknowledge receipt of your submissions dated December 8, 2008, and April 30, May 14 and 22, June 8 and 24, August 13, and September 18, 2009, to NDA 22362.

We acknowledge receipt of your submissions dated January 15, April 30, and June 1, 2009, to NDA 21176/S-022.

NDA 22362 provides for a new formulation of Welchol to be mixed with liquid prior to ingestion for the indications approved in NDA 21176:

- To reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia as monotherapy or in combination with an hydroxymethyl-glutaryl-coenzyme A (HMG CoA) reductase inhibitor (statin).
- To reduce LDL-C levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia as monotherapy or in combination with a statin after failing an adequate trial of diet therapy.
- To improve glycemic control in adults with type 2 diabetes mellitus.

NDA 21176/S-022 provides for the following indication:

- To reduce LDL-C levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia as monotherapy or in combination with a statin after failing an adequate trial of diet therapy.

This supplemental application was submitted in response to our April 4, 2007 Written Request.
We have completed our review of these applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, please submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format as described at http://www.fda.gov/oc/datacouncil/spl.html that is identical to the enclosed labeling (text for the package insert). Upon receipt, we will transmit that version to the National Library of Medicine for public dissemination. For administrative purposes, please designate this submission, “SPL for approved NDA 22-362 and NDA 21176/S-022”, as these applications share a common package insert.

**CARTON AND IMMEDIATE CONTAINER LABELS**

For NDA 22362, submit final printed carton and container labels that are identical to the enclosed carton and immediate container labels as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (October 2005). Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission “Final Printed Carton and Container Labels for approved NDA 22362.” Approval of this submission by FDA is not required before the labeling is used.

**PEDIATRIC RESEARCH EQUITY ACT (PREA)**

All applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred.

**NDA 22362**

Indication #1 - reduction of LDL-C in adults with primary hyperlipidemia as monotherapy or in combination with an HMG CoA reductase inhibitor.

We are waiving the pediatric study requirement for ages 0 through 9 years, inclusive, because necessary studies are impossible or highly impracticable due to the limited population of hypercholesterolemia in this age group. We note that you have fulfilled the pediatric study requirement for ages 10 years to 17 years for this application.

Indication #2 - to improve glycemic control in adults with type 2 diabetes mellitus.

We are waiving the pediatric study requirement for ages 0 through 9 years, inclusive, because the low prevalence of the disease in children below 10 years of age makes the conduct of pediatric studies in this age group highly impracticable.

We are deferring submission of your pediatric study for ages 10 to 17 years for this application because this product is ready for approval for use in adults and the pediatric study has not been completed.

Your deferred pediatric study required by section 505B(a) of the Federal Food, Drug, and Cosmetic Act is a required postmarketing study. The status of this postmarketing study must be reported annually according to 21 CFR 314.81 and section 505B(a)(3)(B) of the Federal Food, Drug, and Cosmetic Act. This required study is listed below.
1. Deferred, 1-year, pediatric efficacy and safety study under PREA for the treatment of type 2 diabetes in pediatric patients ages 10 to 17 years.

Protocol Submitted: May 2010  
Study Initiated: November 2010  
Final Report Submitted: November 2015

Submit final study reports to this NDA. For administrative purposes, all submissions related to this required pediatric postmarketing study must be clearly designated “Required Pediatric Assessment”.

**NDA 21176/S-022**

We are waiving the pediatric study requirement for ages 0 to 9 years, inclusive, because necessary studies are impossible or highly impracticable due to the limited population of hypercholesterolemia in this age group.

We note that you have fulfilled the pediatric study requirement for ages 10 years to 17 years for this application.

**PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert to:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Division of Drug Marketing, Advertising, and Communications  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the package insert(s), at the time of initial dissemination or publication, accompanied by a Form FDA 2253. For instruction on completing the Form FDA 2253, see page 2 of the Form. For more information about submission of promotional materials to the Division of Drug Marketing, Advertising, and Communications (DDMAC), see [www.fda.gov/ceder/ddmac](http://www.fda.gov/ceder/ddmac).

**LETTERS TO HEALTH CARE PROFESSIONALS**

If you issue a letter communicating important safety related information about these drug products (i.e., a “Dear Health Care Professional” letter), we request that you submit an electronic copy of the letter to both the respective NDA and to the following address:

MedWatch  
Food and Drug Administration  
Suite 12B05  
5600 Fishers Lane  
Rockville, MD 20857
REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Kati Johnson, Regulatory Project Manager, at (301) 796-1234.

Sincerely,

{See appended electronic signature page}

Mary H. Parks, M.D.
Director
Division of Metabolism and Endocrinology Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

Enclosure: Combined Package Insert (for both Oral Suspension and Tablets)
Welchol for Oral Suspension:
1.875 gram trade packet
1.875 gram sample packet
1.875 gram trade carton (contains 60 packets)
1.875 gram sample carton (contains 6 packets)
3.75 gram trade packet
3.75 gram sample packet
3.75 gram sample carton (contains 3 packets)
3.75 gram carton (contains 30 packets)